DA
IONS icon

DCF Advisers’s Ionis Pharmaceuticals IONS Stock Holding History

DCF Advisers’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,500
Closed -$45.3K – 87
2025
Q1 		$45.3K Buy
+1,500
New +$49.1K 0.02% 83

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

DCF Advisers's IONS Position: Q2 2026 in Review

DCF Advisers reduced its Ionis Pharmaceuticals (IONS) stake by 33% in Q2 2026, selling an estimated $1.39M and leaving 37,500 shares worth $2.97M. The position accounts for 0.53% of the portfolio, ranked #35.

DCF Advisers first reported a position in IONS in Q2 2024 and has held it in 9 quarters since. The position peaked at $8.15M in Q4 2025. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • DCF Advisers held 37,500 shares of Ionis Pharmaceuticals worth $2.97M as of Q2 2026.
  • DCF Advisers sold 18,500 Ionis Pharmaceuticals shares in Q2 2026, an estimated $1.39M.
  • Ionis Pharmaceuticals made up 0.53% of DCF Advisers's portfolio in Q2 2026, its #35 holding.
  • DCF Advisers first reported a position in Ionis Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • DCF Advisers's Ionis Pharmaceuticals position peaked at $8.15M in Q4 2025.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on DCF Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.